AMG 714

BIOLOGICAL6 trials

Sponsors

Amgen, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Celiac DiseaseIn-situ Small Bowel T-cell LymphomaPsoriasisRheumatoid ArthritisType II Refractory Celiac Disease (RCD-II)Vitiligo

Phase 2

Phase 2 AMG 714 in Rheumatoid Arthritis

CompletedNCT00433875

AmgenRheumatoid Arthritis

Start: 2002-12-31Target: 180Updated: 2007-12-28

AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects

CompletedNCT00443326

Start: 2007-03-31End: 2010-05-31Updated: 2016-01-20

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

CompletedNCT02633020

AmgenIn-situ Small Bowel T-cell Lymphoma, Type II Refractory Celiac Disease (RCD-II)

Start: 2016-04-13End: 2017-05-02Updated: 2019-12-27

A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease

CompletedNCT02637141

AmgenCeliac Disease

Start: 2016-04-13End: 2017-03-14Updated: 2019-12-03

Evaluation of AMG 714 for Vitiligo

CompletedNCT04338581

National Institute of Allergy and Infectious Diseases (NIAID)Vitiligo

Start: 2020-12-11End: 2025-04-02Updated: 2025-12-09

Unknown Phase

AMG 714 Expanded Access Program

AmgenCeliac Disease

Updated: 2025-05-04

Related Papers

Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.

2019-09-0489 citations

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study.

2019-09-0464 citations